In-Person KOL Breakfast: Protalix Presents following Elfabrio®’s Approvals for Fabry Disease in the US and the EU

In-Person KOL Breakfast: Protalix Presents following Elfabrio®’s Approvals for Fabry Disease in the US and the EU

EVENT DETAILS

In-Person KOL Breakfast: Protalix Presents following Elfabrio®’s Approvals for Fabry Disease in the US and the EU
06/27/23 8:00 AM EDT
Event Details
Title In-Person KOL Breakfast: Protalix Presents following Elfabrio®’s Approvals for Fabry Disease in the US and the EU
Date and Time 06/27/23 8:00 AM EDT
Description

Hosted by Protalix Biotherapeutics (NYSE American: PLX)

WHERE: Lotte Palace Hotel, New York
WHEN: Tuesday, June 27, 2023
8:00 – 8:30 AM: Breakfast
8:30 – 10:30 AM: KOL & Company Presentations

Join us in-person for a KOL Breakfast with Protalix Biotherapeutics, discussing the recent FDA approval of Elfabrio® (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease.

Event agenda:

1. Ankit Mehta, MD, FASN (Baylor University Medical Center) will discuss the opportunity for Elfabrio® to address the unmet needs in Fabry disease.
2. Giacomo Chiesi, Head of Chiesi Global Rare Diseases, Protalix’s commercial partner, will discuss Chiesi’s commercial capabilities.
3. Protalix leadership will provide insight into the Company's strategy and future plans.

A live question and answer session will follow the formal presentations.

For those unable to attend in-person, the event will be available via a live webcast.

IMPORTANT INFORMATION

Registration Information

You are required to register in advance for the event.

Q&A Information

If you would like to ask a question during the live Q&A, please submit your request to questions@lifesciadvisors.com.

Register and Attend